SCHEMBL10029043

SCHEMBL10029043

OCC(O)CNC(c1ccccc1)c1ccccc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 2/20 0.54
MTOR P42345 1/20 0.54
GRM7 Q14831 1/20 0.54
CYP3A4 P08684 1/20 0.52
ALOX15 P16050 1/20 0.52
TSHR P16473 1/20 0.52
ALDH1A1 P00352 2/20 0.46
LMNA P02545 2/20 0.46
HSD17B10 Q99714 1/20 0.46
L3MBTL1 Q9Y468 2/20 0.45
KDM4E B2RXH2 1/20 0.45
ABCB1 P08183 1/20 0.44
AOC3 Q16853 3/20 0.42
ADRB3 P13945 2/20 0.40
ADRB2 P07550 1/20 0.39
ADRB1 P08588 1/20 0.39
CYP2D6 P10635 1/20 0.39
ATM Q13315 1/20 0.39
BCAT2 O15382 1/20 0.38
NPC1 O15118 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11592029 0.82 RAB9A (0.52) RAB9AMTORGRM7CYP3A4ALOX15
SCHEMBL27539055 0.81 RAB9A (0.60) RAB9AMTORGRM7CYP3A4ALOX15
SCHEMBL1780965 0.81 AKT1 (0.47) LMNAAOC3
SCHEMBL1573478 0.80 MTOR (0.54) RAB9AMTORGRM7CYP3A4ALOX15
SCHEMBL9728971 0.79 AOC3 (0.52) CYP3A4ALOX15TSHRALDH1A1LMNA
SCHEMBL31000817 0.78 MTOR (0.52) RAB9AMTORGRM7CYP3A4ALOX15
SCHEMBL28512852 0.78 MTOR (0.52) RAB9AMTORGRM7CYP3A4ALOX15
SCHEMBL20049938 0.77 CYP2D6 (0.69) RAB9AALDH1A1ABCB1ADRB3ADRB2
SCHEMBL15591917 0.76 GRM7 (0.65) RAB9AMTORGRM7CYP3A4ALOX15
Iodomethane SCHEMBL1573608 0.76 MTOR (0.48) RAB9AMTORGRM7CYP3A4ALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8207355-B2 Method for preparing azetidine derivatives SANOFI-AVENTIS (FR) 2012-06-26 US disclosed
US-20110118481-A1 METHOD FOR PREPARING AZETIDINE DERIVATIVES SANOFI-AVENTIS (FR) 2011-05-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110118481-A1 METHOD FOR PREPARING AZETIDINE DERIVATIVES QDPR, AZI2, NISCH RAB9A 52/4885MTOR 2159/4885GRM7 4785/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.